Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study consisted of two parts. In Part 1 the study enrolled 38 patients (Step 1 Simon 2 step design) after which Step 2 was opened and the total enrollment target for the study (n=63) was exceeded due to a rapid enrollment (78 patients were entered). Part 2 of the study did not open due to the final overall insufficiency of efficacy observed in 78 patients. Sunitinib (SU011248) was administered orally daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg with provision for dose reduction based on tolerability. All patients received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria were met. After discontinuation of treatment, patients were followed up in order to collect information on further antineoplastic therapy and survival.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental | 50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sunitinib | Drug | 50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed |
| Measure | Description | Time Frame |
|---|---|---|
| Best Overall Response | Number of patients with best overall response = complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study ≥4 weeks after initial documentation of response. CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
| Objective Response (Complete Response (CR) or Partial Response (PR)) | Number of patients with Objective Response (OR): confirmed CR or confirmed PR according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Benefit Response (CBR)-Complete Response (CR), Partial Response (PR) or Stable Disease (SD) With Duration ≥ 24 Weeks | Number of patients with Clinical Benefit Response: confirmed CR, confirmed PR or stable disease (SD) for at least 24 weeks on study according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progessive disease (PD) taking as a reference the smallest sum of the longest dimensions since the treatment started. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Nanjing | Jiangsu | 210002 | China | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
This study used a Simon 2-stage design with objective response rate (ORR) as the primary efficacy endpoint. Enrollment was halted after Part 1 Stage 2 because the minimum number of responding subjects required to proceed to Part 2 was not reached. Further subject enrollment therefore ended after 78 subjects had been enrolled and treated on Part 1.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 50 mg Sunitinib | Sunitinib was administered orally daily for 4 weeks followed by a 2-week off-treatment period (Schedule 4 weeks on drug / 2 weeks off) in each cycle. The starting dose was 50 mg daily with provision for dose interruption and/or reduction based on tolerability. All subjects received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, withdrawal of subject consent, or other withdrawal criteria were met. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or clinical benefit response for at least 24 weeks on study |
| Duration of Response (CR or PR) | Time from the first documentation of confirmed objective response (CR or PR) to the first documentation of disease progression or to death due to any cause. CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | Day 28 of Cycle 1 and Day 28 of Cycles thereafter or death due to cancer |
| Progression-Free Survival | Time from start of study treatment to first documentation of objective tumor progression, or to death due to any cause. PFS was calculated as (first event date minus the date of first dose plus 1) divided by 7. | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or death |
| Time to Tumor Progression (TTP) | Time from the start of study treatment to the first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose plus 1) divided by 7. | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
| Overall Survival | Time from the date of first dose of study medication to the date of death due to any cause. OS was calculated as (date of death minus the date of first dose date plus 1) divided by 7. | From start of study treatment until death |
| Beijing |
| 100036 |
| China |
| Pfizer Investigational Site | Beijing | China |
| Pfizer Investigational Site | Guangzhou | 510515 | China |
| Pfizer Investigational Site | Hong Kong | Hong Kong |
| Pfizer Investigational Site | Shatin | Hong Kong |
| Pfizer Investigational Site | Ancona | 60020 | Italy |
| Pfizer Investigational Site | Genova | 16132 | Italy |
| Pfizer Investigational Site | Kashiwa | Chiba | Japan |
| Pfizer Investigational Site | Suntougun | Shizuoka | Japan |
| Pfizer Investigational Site | Chuo-ku | Tokyo | Japan |
| Pfizer Investigational Site | Porto | 4200-072 | Portugal |
| Pfizer Investigational Site | Seoul | 110-744 | South Korea |
| Pfizer Investigational Site | Seoul | 120-752 | South Korea |
| Pfizer Investigational Site | Seoul | 135-710 | South Korea |
| Pfizer Investigational Site | Seoul | 138-736 | South Korea |
| Pfizer Investigational Site | Kwei-Shan | Taoyuan | 333 | Taiwan |
| Pfizer Investigational Site | Taipei | 100 | Taiwan |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 50 mg Sunitinib | Sunitinib was administered orally daily for 4 weeks followed by a 2-week off-treatment period (Schedule 4 weeks on drug / 2 weeks off) in each cycle. The starting dose was 50 mg daily with provision for dose interruption and/or reduction based on tolerability. All subjects received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, withdrawal of subject consent, or other withdrawal criteria were met. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Best Overall Response | Number of patients with best overall response = complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study ≥4 weeks after initial documentation of response. CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | Intent-to-treat (ITT) population includes all patients enrolled in the study that received at least 1 dose of study medication. | Posted | Number | participants | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
|
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Clinical Benefit Response (CBR)-Complete Response (CR), Partial Response (PR) or Stable Disease (SD) With Duration ≥ 24 Weeks | Number of patients with Clinical Benefit Response: confirmed CR, confirmed PR or stable disease (SD) for at least 24 weeks on study according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progessive disease (PD) taking as a reference the smallest sum of the longest dimensions since the treatment started. | ITT population | Posted | Number | participants | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or clinical benefit response for at least 24 weeks on study |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Response (CR or PR) | Time from the first documentation of confirmed objective response (CR or PR) to the first documentation of disease progression or to death due to any cause. CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | ITT population | Posted | Mean | Full Range | weeks | Day 28 of Cycle 1 and Day 28 of Cycles thereafter or death due to cancer |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Progression-Free Survival | Time from start of study treatment to first documentation of objective tumor progression, or to death due to any cause. PFS was calculated as (first event date minus the date of first dose plus 1) divided by 7. | ITT population | Posted | Median | 95% Confidence Interval | weeks | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or death |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Time to Tumor Progression (TTP) | Time from the start of study treatment to the first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose plus 1) divided by 7. | ITT population | Posted | Median | 95% Confidence Interval | weeks | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Overall Survival | Time from the date of first dose of study medication to the date of death due to any cause. OS was calculated as (date of death minus the date of first dose date plus 1) divided by 7. | ITT population | Posted | Median | 95% Confidence Interval | weeks | From start of study treatment until death |
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Objective Response (Complete Response (CR) or Partial Response (PR)) | Number of patients with Objective Response (OR): confirmed CR or confirmed PR according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a ≥30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. | ITT population | Posted | Number | participants | From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 50 mg Sunitinib | Sunitinib was administered orally daily for 4 weeks followed by a 2-week off-treatment period (Schedule 4 weeks on drug / 2 weeks off) in each cycle. The starting dose was 50 mg daily with provision for dose interruption and/or reduction based on tolerability. All subjects received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, withdrawal of subject consent, or other withdrawal criteria were met. | 30 | 78 | 78 | 78 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Disseminated intravascular coagulation | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Cardiac arrest | Cardiac disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Sinus bradycardia | Cardiac disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Heterophoria | Eye disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Peritonitis | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Salivary gland pain | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Disease progression | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Malaise | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Mucosal inflammation | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Performance status decreased | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Jaundice | Hepatobiliary disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Jaundice cholestatic | Hepatobiliary disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA v11.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA v11.0 | Systematic Assessment |
| |
| Brain herniation | Injury, poisoning and procedural complications | MedDRA v11.0 | Systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA v11.0 | Systematic Assessment |
| |
| Stent occlusion | Injury, poisoning and procedural complications | MedDRA v11.0 | Systematic Assessment |
| |
| Anorexia | Metabolism and nutrition disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Tumour compression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v11.0 | Systematic Assessment |
| |
| Brain stem haemorrhage | Nervous system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Cerebral infarction | Nervous system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Hypopnoea | Respiratory, thoracic and mediastinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA v11.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Leukopenia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Abdominal distension | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Gingivitis | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Face oedema | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA v11.0 | Systematic Assessment |
| |
| Malaise | General disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Mucosal inflammation | General disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Oedema | General disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (v11.0) | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| Blood alkaline phosphatase increased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| C-reactive protein increased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| Red blood cell count decreased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA (v11.0) | Systematic Assessment |
| |
| Anorexia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hypoproteinaemia | Metabolism and nutrition disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Peripheral sensory neuropathy | Nervous system disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Skin discolouration | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Skin exfoliation | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Skin lesion | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Yellow skin | Skin and subcutaneous tissue disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA (v11.0) | Systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | MedDRA (v11.0) | Systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of < 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), < 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.govCallCenter@pfizer.com |
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077210 | Sunitinib |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| Progressive Disease |
|
| Not Evaluable |
|
| Missing |
|
| Participants |
|
|
|
|
|
|
|
|
|